Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short versus extended carbapenem therapy for high-risk febrile neutropenia with fever of unknown origin
2014-001546-25Phase 4Completed
- Sponsor
- VU University Medical Center
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of imipenem + cilastatin and meropenem in febrile neutropenia (FN) and fever of unknown origin (FUO) (2 arms), sponsored by VU University Medical Center. Started Nov 2014; status: completed.
02
Drugs
imipenem + cilastatinmeropenem
03
Conditions
febrile neutropenia (FN)fever of unknown origin (FUO)
Beyond the preview
Go deeper on 2014-001546-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001546-25.